Metabolic research has rarely moved this fast. The publication of Jastreboff et al. in the New England Journal of Medicine in 2023 placed retatrutide firmly on the radar of every serious lab working on energy regulation and body composition research. A triple receptor agonist — simultaneously engaging GIP, GLP-1, and glucagon receptors — retatrutide produced weight-reduction outcomes in that phase 2 trial that outpaced dual-agonist comparators, prompting Eli Lilly to advance the TRIUMPH phase 3 programme. For UAE-based research teams operating out of facilities in Business Bay, Dubai Science Park, DXB Airport Free Zone, and Abu Dhabi's emerging life science corridor, this translated into a clear surge in procurement requests for retatrutide vials throughout 2025 and into 2026.
MOTS-c entered the mainstream research literature through Lee et al. (2015, Cell Metabolism), which identified this 16-amino-acid peptide — encoded within the 12S rRNA gene of mitochondrial DNA — as a signalling molecule influencing whole-body metabolic homeostasis. Its proposed primary mechanism involves AMPK activation and FOXO1 regulation in skeletal muscle, with downstream effects on glucose uptake and fatty acid oxidation. The framing of MOTS-c as a "mitochondrial hormone" sparked interest precisely because it operates upstream of many metabolic processes that whole-organism agonists like retatrutide address from the receptor side.
The combination hypothesis is mechanistically clean: one peptide works top-down (receptor-level signalling modulating appetite, glucagon dynamics, and incretin response), the other works bottom-up (cellular energy sensing originating at the mitochondrial level). Whether this dual-axis approach produces complementary or synergistic effects in research models is an open and actively contested question — but it is one that a growing number of UAE lab teams are asking. Researchers in Sharjah university labs, Abu Dhabi private research entities, and Dubai-based investigational facilities have all queried REVIVE LAB UAE about this specific combination over the past six months, making it the most-requested peptide stack of 2026 in the UAE research context.
Retatrutide is a synthetic acylated peptide acting as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors. This three-receptor profile distinguishes it structurally from semaglutide (GLP-1 selective) and tirzepatide (dual GIP/GLP-1). The addition of the glucagon receptor agonism component is particularly relevant for energy expenditure research, since glucagon is a known driver of hepatic glucose output, thermogenesis, and lipolysis — effects that neither a GLP-1 agonist nor a dual GIP/GLP-1 agonist engages to the same degree.
The Jastreboff et al. 2023 NEJM trial enrolled 338 adults across multiple dose cohorts over 24 weeks, with extensions to 48 weeks. The research titration framework used in that trial — ascending from 2mg through 4mg to 8mg in successive dose steps — has become the most consistently referenced dose ladder in the peptide research community globally, and the UAE is no exception. Research teams sourcing retatrutide in the UAE are routinely working with these published reference ranges when designing their own model-based protocols, and the three figures (2mg, 4mg, 8mg) appear in virtually every lab discussion about retatrutide protocol design. The Eli Lilly TRIUMPH phase 3 programme has since published further readouts that expand the evidentiary base, reinforcing the dose-dependent relationship established in phase 2 and providing additional data on the tolerability profile at each tier.
For researchers, the structurally important insight from the phase 2 data is not simply the headline outcomes but the step-up nature of the titration: the tolerability profile varied meaningfully by how quickly researchers moved between dose levels. A protocol that rushes to the higher reference-range too early in the timeline introduces confounding tolerability effects into the data. This makes the sequencing and pacing of retatrutide titration a design-level decision, not merely a logistics one.
REVIVE LAB UAE stocks retatrutide in two configurations: 5mg lyophilised vials and 10mg lyophilised vials. The choice matters for protocol architecture. If a research programme operates at the lower reference range (consistent with the 2mg reference point in the published titration ladder), a 5mg vial provides granularity appropriate for smaller model sets and shorter protocols without leaving significant unconsumed peptide in each vial. For protocols running at the upper reference range, or for lab programmes managing eight-week-plus research cycles, the 10mg vial reduces reconstitution frequency and limits freeze-thaw exposure events — both of which matter for peptide integrity across a multi-week protocol.
| Vial Size | Best Fit For | Published Reference Range Context |
|---|---|---|
| Retatrutide 5mg | Short protocols, lower reference dose work, smaller model sets | 2mg titration tier (Jastreboff et al. 2023) |
| Retatrutide 10mg | Multi-week protocols, upper reference dose range, reduced reconstitution events | 4mg–8mg titration tiers (Jastreboff et al. 2023) |
5mg and 10mg lyophilised vials available now at REVIVE LAB UAE. Same-day delivery to Dubai JBR, Business Bay, Marina, DIFC, Dubai Healthcare City. 24h delivery to Abu Dhabi and Sharjah. Cold-chain maintained. Cash on delivery available.
Buy Retatrutide UAE — Same-Day Dubai Dispatch from REVIVE LAB UAEMOTS-c (Mitochondria-derived peptide from the Open reading frame Ten S locus) was characterised in the landmark Lee et al. 2015 Cell Metabolism paper, which demonstrated that this 16-amino-acid peptide, encoded within the mitochondrial 12S rRNA gene, acts as a retrograde signalling molecule influencing systemic metabolic homeostasis. The paper reported that MOTS-c treatment in mouse models activated AMPK and modulated FOXO1 in skeletal muscle, improving insulin sensitivity and glucose utilisation — effects that were not replicated when the same peptide was administered in an AMPK-deficient context, strongly supporting an on-target mechanism rather than a non-specific effect.
What makes MOTS-c conceptually interesting as a research companion to retatrutide is the structural level at which it intervenes. Retatrutide operates via membrane receptor agonism: it binds GIP, GLP-1, and GCG receptors on cell surfaces and initiates downstream intracellular signalling cascades. MOTS-c, by contrast, appears to originate inside the mitochondrial matrix and to influence nuclear gene expression through pathways involving the folate and methionine cycles. This is not receptor pharmacology in any conventional sense — it is a peptide that functions analogously to a retrograde mitochondrial regulatory signal, a category of biology that remains mechanistically distinct from anything that receptor agonists can access.
For UAE researchers, the practical upshot of this distinction is that you are not simply stacking two peptides that work on the same pathway with additive effect and hope for dose-equivalence. You are — in research hypothesis terms — addressing metabolic regulation at two different structural levels of the cell simultaneously: the plasma membrane and the mitochondrial matrix. Whether that produces meaningful, distinguishable effects in a given model depends on study design, measurement endpoints, and the specific research questions being posed.
Unlike retatrutide, MOTS-c does not have a published phase 2 human trial of comparable scope and statistical power. The evidence base for MOTS-c remains primarily pre-clinical, anchored to Lee et al. 2015 and subsequent cell and animal work that has followed in the decade since. This means research teams approaching a dual-peptide protocol must hold an evidentiary asymmetry clearly in mind: retatrutide has a well-characterised published human titration ladder with dose-response data; MOTS-c has a strong mechanistic characterisation from pre-clinical models but not the same clinical depth. How each compound is positioned in a protocol design — and how claims are framed about observed effects — should accurately reflect that asymmetry.
Research teams in the UAE structuring a dual-peptide protocol around retatrutide and MOTS-c typically approach design through three interlinked decisions: sequencing (which compound is introduced first and when the second is added), endpoint selection (what metabolic markers the protocol is built to interrogate), and washout architecture (whether the compounds are studied in isolation before combination, or introduced in parallel from the outset with appropriate control groups).
The most commonly discussed sequencing approach among UAE research labs starts with a retatrutide-alone phase before MOTS-c is introduced. The logic is straightforward: retatrutide has the more characterised titration reference framework. Researchers familiar with the Jastreboff 2023 dose ladder can establish a stable reference-range dose state with retatrutide before adding the second variable. Running both compounds from day one makes it structurally harder to attribute observed effects to one component versus the other — particularly for endpoints that both compounds may plausibly influence, such as glucose homeostasis markers or body composition changes in animal models.
A parallel-introduction approach is more defensible when the research question specifically concerns the interaction between the two mechanisms rather than either compound in isolation. In this design, appropriate single-compound control groups (retatrutide alone, MOTS-c alone, vehicle control) are run alongside the stacked group. This demands a larger model set but provides cleaner data on whether the combination produces effects that neither compound produces individually. Research entities with sufficient capacity in Abu Dhabi and Dubai Science Park have adopted this four-arm design for exactly this reason.
Given the distinct mechanisms involved, relevant research endpoints for a retatrutide + MOTS-c protocol typically span both systemic and cellular measurement levels:
The dual-track measurement approach — systemic metabolic markers plus cellular mechanistic markers — is what distinguishes a retatrutide + MOTS-c protocol from a retatrutide-only protocol in terms of what it can and cannot answer. A research team measuring only systemic outcomes will not be able to speak to the MOTS-c mechanism. Including AMPK phosphorylation and mitochondrial function endpoints is what makes the stack protocol scientifically specific rather than simply additive.
| Protocol Phase | Retatrutide | MOTS-c | Key Research Rationale |
|---|---|---|---|
| Phase 1 — Baseline stabilisation | Titration initiation at 2mg reference range | Not introduced; washout baseline | Establish retatrutide-alone baseline; avoid multi-variable confound |
| Phase 2 — Dose escalation | Step-up to 4mg reference range per protocol | Not introduced | Achieve stable receptor agonism profile before stacking |
| Phase 3 — Stack introduction | Maintain or escalate toward 8mg reference range | Introduce per protocol design | Test dual-mechanism hypothesis with retatrutide-stable baseline |
| Phase 4 — Washout and endpoint collection | Taper or cessation per protocol | Taper or cessation per protocol | Assess reversibility; collect primary endpoint data |
For UAE-based researchers — whether operating from a formal laboratory in Dubai's Al Quoz industrial corridor, a research facility near DXB Airport Free Zone, a private research operation in Business Bay, or a university-affiliated lab in Abu Dhabi or Sharjah — the sourcing question for peptides like retatrutide is more nuanced than finding a supplier who lists the product. Several quality factors materially affect research outcomes and separate suppliers that are genuinely useful to lab operations from those that are not.
In a UAE summer — June through September — ambient outdoor temperatures regularly exceed 45°C in Dubai and across the Emirates. Peptides are temperature-sensitive biological molecules. Lyophilised vials tolerate ambient conditions better than reconstituted solutions, but shipping still requires appropriate cold packaging to maintain potency from dispatch to laboratory bench. A supplier maintaining inventory locally in the UAE and offering same-day delivery within Dubai has a structural cold-chain advantage over international suppliers routing orders through UAE customs and last-mile couriers without controlled-temperature continuity. This is not a marginal consideration — it is the difference between receiving a research-grade compound and receiving a degraded analogue of unknown potency. REVIVE LAB UAE maintains UAE-based stock, enabling same-day dispatch with validated cold-chain packaging rather than multi-day international shipment through warm-chain gaps.
Research-grade peptides should arrive with HPLC purity data and mass spectrometry identity confirmation as standard documentation. For retatrutide, where the molecular weight and amino acid sequence are well-established from published literature and Eli Lilly's public disclosures, these documents are a baseline minimum — not a premium add-on that justifies higher pricing. Research teams that have encountered inconsistent results in protocols using undocumented peptide sources know that purity confirmation is the first sourcing question to ask. A supplier unwilling or unable to provide this documentation should not be receiving orders for research-grade peptides regardless of price.
Not all UAE researchers operate on the same logistics cadence. A Dubai-based lab with a protocol in progress may need same-day retatrutide delivery to maintain an uninterrupted research timeline. An Abu Dhabi facility or a Sharjah university department typically plans on a 24-hour horizon. REVIVE LAB UAE structures logistics to serve both: orders placed before 12:00 GST qualify for same-day dispatch to Dubai (covering Palm Jumeirah, JBR, Marina, DIFC, Business Bay, Dubai Healthcare City, Al Quoz, and beyond); Abu Dhabi and Sharjah orders dispatch the same day for next-day arrival. Cash on delivery is available for Dubai orders, removing pre-payment friction for research teams that prefer that settlement model. Discreet packaging is standard on all orders — plain outer packaging with no product identification on the exterior. This is not a premium option; it is how all REVIVE LAB UAE research peptide orders ship.
Retatrutide arrives from REVIVE LAB UAE as a lyophilised powder. Standard reconstitution for research use employs bacteriostatic water (BAC water), which extends the usable life of the reconstituted solution relative to standard sterile water by inhibiting microbial growth during storage. The reconstituted solution should be maintained at 2–8°C and handled according to the lab's validated stability protocol. Repeated freeze-thaw cycles of the reconstituted solution degrade peptide integrity over time — for multi-week protocols, the practice of reconstituting from a fresh vial at each new protocol phase is preferable to storing a single reconstituted batch. The 5mg and 10mg vial sizing from REVIVE LAB UAE accommodates this: a 10mg vial provides enough material for multi-week use while reducing the number of reconstitution events compared to multiple 5mg vials.
MOTS-c, as a 16-amino-acid peptide with a compact and well-defined primary structure, is also typically supplied lyophilised and handles similarly. The same cold-chain principles apply. Given that MOTS-c's proposed mechanism involves intracellular and nuclear gene expression modulation rather than extracellular receptor binding, ensuring that the compound arrives and is stored with full structural integrity is particularly important — a degraded MOTS-c preparation in a protocol may not simply produce a "no effect" finding but may instead produce a "no functional peptide was present" confound that invalidates the experimental design entirely.
For labs in Dubai and Abu Dhabi handling both compounds simultaneously within the same protocol, rigorous separate storage labelling, independent reconstitution logs, and separate lot-number documentation chains are essential. This is good research practice in any context; it becomes especially important when two investigational compounds are running concurrently, as a stack protocol inherently requires, and where the data value depends on being able to attribute effects to specific compounds or to their combination.
The UAE is increasingly a substantive node in global peptide research, not merely a consumer-side procurement market. Several factors have converged to make this the case by 2026. Life science infrastructure in both Dubai and Abu Dhabi has expanded significantly: Dubai Science Park now hosts multiple research entities spanning pharmaceutical, biotechnology, and investigational compound research. Abu Dhabi's Cleveland Clinic Abu Dhabi ecosystem and the broader Masdar City research corridor have brought institutional research capacity that simply did not exist in the Emirates five years ago. The regulatory environment for research-use compounds is navigable for legitimate research entities with appropriate institutional affiliation and documentation.
For peptide suppliers, this means the UAE demand profile looks materially different from a consumer supplement market. The dominant buyers of retatrutide in the UAE are research labs, investigational research entities, and procurement teams operating on lab-cadence purchasing cycles — not individual end-users. REVIVE LAB UAE was structured specifically to serve this buyer profile: B2B-first, research documentation-first, logistics designed around lab procurement cycles and cold-chain requirements rather than retail convenience. The minimum order architecture, documentation provision, and delivery capabilities all reflect that.
The growth in MOTS-c interest from UAE research teams specifically tracks the broader mitochondria-derived peptide (MDP) research wave that followed the Lee et al. 2015 publication and subsequent work classifying MDPs as a functional peptide category with systemic signalling roles. Researchers who were already sourcing retatrutide from REVIVE LAB UAE for metabolic research programmes began asking about MOTS-c as a complementary compound with a distinct mechanism from mid-2025 onward. That pairing has become the most frequently requested dual-compound protocol inquiry reaching REVIVE LAB UAE's research desk in 2026 — driven almost equally by labs in Dubai and research entities based in Abu Dhabi and Sharjah.
Yes. REVIVE LAB UAE stocks retatrutide 5mg and 10mg vials for research purposes. Orders placed before 12:00 GST qualify for same-day dispatch within Dubai, with 24h delivery across the UAE including Abu Dhabi, Sharjah, and the Northern Emirates. Cash on delivery is available for Dubai orders. All shipments are dispatched with cold-chain packaging. Visit the retatrutide product page for current stock confirmation and ordering.
Yes. All retatrutide orders from REVIVE LAB UAE ship in plain, unmarked outer packaging with no product branding visible on the exterior. Cold-chain integrity is maintained throughout the full delivery chain. Orders arrive in standard courier packaging indistinguishable from any other parcel — this is standard practice for every research peptide order dispatched by REVIVE LAB UAE, not a separately priced option.
REVIVE LAB UAE currently stocks retatrutide in 5mg and 10mg lyophilised vials, both held in temperature-controlled storage. The 10mg vial is the preferred selection for multi-week research protocols, particularly those referencing the upper titration tiers from the Jastreboff et al. 2023 NEJM framework (4mg and 8mg reference ranges), as it reduces the number of reconstitution events needed across a longer protocol. The 5mg vial suits shorter research windows or protocols working at the lower 2mg reference range. Both are in stock and available for same-day dispatch to Dubai.
5mg & 10mg vials. Retatrutide same-day delivery Dubai. 24h delivery Abu Dhabi & Sharjah. Discreet packaging as standard. Cash on delivery available. Cold-chain guaranteed from our UAE stock to your lab.
Buy Retatrutide UAE — Order Now from REVIVE LAB UAE